Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab

  1. Natacha Madelon
  2. Nelli Heikkilä
  3. Irène Sabater Royo
  4. Paola Fontannaz
  5. Gautier Breville
  6. Kim Lauper
  7. Rachel Goldstein
  8. Alba Grifoni
  9. Alessandro Sette
  10. Claire-Anne Siegrist
  11. Axel Finckh
  12. Patrice H. Lalive
  13. Arnaud M. Didierlaurent
  14. Christiane S. Eberhardt

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1001/jamaneurol.2022.0245
  2. ScreenIT

    SciScore for 10.1101/2021.12.20.21268128: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: This prospective observational study has been carried out since March 2021 at the Geneva University Hospitals, Switzerland, according to the principles of Good Clinical Practice and was approved by the Geneva Cantonal Ethics Commission (2021-00430).
    Consent: Informed consent was obtained from all participants and more study details are found elsewhere5.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Anti-SARS-CoV-2 nucleoprotein (anti-N) total antibodies and anti-SARS-CoV-2 RBD (anti-receptor binding domain) total antibodies were measured, and seroconversion was defined as > 0.8 IU/ml for the anti-RBD antibodies and > 1 cut-off index (COI) for anti-N antibodies as described previously5.
    Anti-SARS-CoV-2 nucleoprotein
    suggested: None
    anti-N
    suggested: None
    anti-SARS-CoV-2 RBD (anti-receptor binding domain) total antibodies were measured,
    suggested: None
    anti-RBD
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistical analysis was performed with GraphPad Prism software (version 8.0.2).
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.12.20.21268128v1 on medRxiv